78. Hypopituitarism Clinical trials / Disease details
Clinical trials : 494 / Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04938466 (ClinicalTrials.gov) | August 5, 2021 | 16/6/2021 | Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy | Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy | Growth Hormone Deficiency;Growth Hormone Treatment | Drug: Long-Acting Growth Hormone (LAGH) | University of Minnesota | NULL | Recruiting | 2 Years | 13 Years | All | 80 | United States |